Oxford Researchers Map Multi-Organ Damage Trajectories in Hypertensive Pregnancy to Predict Long-Term Cardiovascular Risk
Key Insights
The HyPrevent platform has assembled a deeply phenotyped longitudinal cohort of over 3,600 participants to study how hypertension during pregnancy affects the heart, brain, and blood vessels across the life course.
Researchers developed a unified global organ-damage risk score (HyperScore) and identified distinct disease progression pathways (HyperTrajectories) linked to mortality and advanced organ damage.
The Lapidaire Group investigates postpartum brain and microvascular changes using multimodal imaging and a novel portable device (VITA) to detect early cerebrovascular and microvascular alterations.
A comprehensive research program at the University of Oxford is redefining how clinicians understand the long-term cardiovascular and cerebrovascular consequences of hypertensive disorders of pregnancy (search). Through the HyPrevent platform—facilitated by the Medical Research Council (MRC)—and complementary brain imaging initiatives led by the Lapidaire Group, researchers are building a multi-organ, life-course picture of how pregnancy-related hypertension accelerates organ damage and influences disease trajectories decades beyond childbirth.
The HyPrevent cohort, based in the Cardiovascular Clinical Research Facility within Oxford's Radcliffe Department of Medicine, has enrolled more than 3,600 participants. It represents a deeply phenotyped longitudinal dataset and biobank that integrates blood samples, blood pressure measurements, electrocardiography, echocardiography, and multimodal MRI of the heart, brain, kidney, and liver.
HyperScore and HyperTrajectories: Mapping Organ Damage
A key computational advance emerging from HyPrevent is the development of a unified global organ-damage risk score, termed HyperScore, alongside the identification of distinct organ-specific disease progression pathways called HyperTrajectories. Each HyperTrajectory has been associated with different clinical outcomes, including mortality and advanced damage in the heart, brain, and vascular system. This framework enables researchers to characterize multi-organ damage in hypertension with unprecedented granularity, potentially allowing clinicians to stratify patients based on their individual risk profiles.
Brain Health and Microvascular Imaging
Complementing the HyPrevent work, the Lapidaire Group focuses specifically on how hypertensive disorders of pregnancy (search) affect brain health over time. The group notes that these disorders are associated with an earlier occurrence of stroke (search) and cognitive impairment (search) than would be expected given baseline characteristics and blood pressure levels. By imaging postpartum brain and microvascular changes in women with and without a history of hypertensive disorders of pregnancy, the researchers aim to clarify the mechanisms driving these adverse neurological outcomes.
The Lapidaire Group works closely with the Leeson Group to integrate brain imaging findings within the broader multi-modal, multi-organ characterization of hypertensive disease trajectories, building a more complete understanding of how pregnancy complications shape long-term cardiovascular and neurological outcomes.
VITA: A Novel Portable Imaging Device
A distinctive technological element of the research is the Vascular Imaging Tool for the Auricle (VITA), developed in collaboration with Dr. Elliot Bentine at Oxford's Department of Physics. VITA is a portable, non-invasive medical imaging device that measures characteristics of small vessels and blood cells. Its ease of use makes it suitable for resource-poor settings and community care. The device is being deployed to study microvascular health in research participants with a range of cardiovascular health risks related to blood pressure and pregnancy history, with deep phenotyping measures—including cardiac and brain MRI, retinal vascular imaging, blood samples, and blood pressure measures—collected in parallel to investigate the relationship between microvascular health in the ear and end-organ health.
Clinical validation of VITA's blood cell measurements against gold standards is funded by the MRC and the Medical Life Science and Translational Fund, supported by the MRC and the Wellcome Trust. The VITA-A study tests the device's ability to measure red blood cell characteristics in healthy volunteers, while the NITA study evaluates the same in pregnant women. VITA is also being used to assess microvascular health in patients admitted to the Acute Ambulatory Unit.
Clinical Translation and Infrastructure
The research forms an integral component of the NIHR Oxford Biomedical Research Centre (search) (BRC) Cardiovascular Theme. Investigators co-lead the Oxford Cardiovascular Disease and Pregnancy Research Collaborative (CDPRC), a cross-disciplinary network spanning basic science, imaging, clinical research, and global health. The collaborative focuses on understanding how cardiovascular conditions arising in pregnancy relate to long-term heart and vascular disease, with the goal of informing better prevention and management across the life course.
In parallel, the group runs a clinical postnatal hypertension service within the Oxford University Hospitals NHS Foundation Trust (search). With supplementary BRC funding, the service is recruiting to the FLOWER study, which explores cardiovascular health after a new diagnosis of a range of cardiovascular conditions in pregnancy.
Data Resources Supporting Discovery
Two additional data resources bolster the research infrastructure. The EchoVision dataset contains all clinical reports from routine transthoracic echocardiograms performed across Oxford University Hospitals NHS Foundation Trust (search) from 2017 to present, currently holding over 140,000 clinical reports linked to patient comorbidity data, hospital admission details, and laboratory tests. The EVAREST study, conducted from 2015 to 2023, recruited over 18,000 patients who underwent stress echocardiography to identify coronary artery disease (search) and other cardiac conditions, with long-term follow-up data available for a subset of patients through NHS England.
Patient and public involvement and engagement is described as integral to the cardiovascular research, with individuals with lived experience and members of the public contributing insights into what matters to those affected and the practical challenges of research participation.